NCT01348919: Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma |
|
|
| Completed | 1/2 | 11 | US, RoW | CEP-18770, Delanzomib, Lenalidomide, Dexamethasone | Teva Branded Pharmaceutical Products R&D, Inc. | Multiple Myeloma | 03/13 | 03/13 | | |